Zai Lab
Ning Wang has extensive work experience in the field of oncology. Currently, Ning serves as the Senior Medical Director in oncology at Zai Lab, starting in October 2021. Prior to this role, Ning worked at Eli Lilly and Company from November 2017 to October 2021 as an Associate Medical Director in oncology. Before joining Eli Lilly and Company, Ning held various roles at Changhai Hospital, including Associate Professor and oncologist from September 2017 to October 2017, and Medical Oncologist from September 2005 to August 2017.
Ning Wang holds a Doctor of Medicine (M.D.) degree in clinical oncology, which was obtained from The Second Military Medical University. Prior to that, they earned a Master's degree in clinical oncology from the same university. Ning began their educational journey at The Second Military Medical University, where they received a Bachelor's degree in Medicine.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.